July 10th 2025
Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
Kaposi Sarcoma: A Brief Review
November 1st 2006Generalized papular, erythematous, nonpruritic, hyperpigmented lesions had appeared on the face, arms, chest, and abdomen of a 25-year-old homosexual man with AIDS during the previous month. Anupama Ravi, MD, of Atlanta also noted purple-red, nodular lesions in the right conjunctiva and oral cavity, especially the lower gingiva. Other pertinent physical findings included facial edema and hepatosplenomegaly.
AASLD: Tyzeka Bests Epivir at HBV Control at Two Years
October 30th 2006BOSTON -- The newly approved nucleoside analog Tyzeka (telbivudine) was superior to Epivir (lamivudine) at reducing hepatitis B virus to undetectable levels at two years of follow-up, reported investigators in studies presented here.
Observation Advised for Most Children with Acute Otitis Media
October 20th 2006UTRECHT, The Netherlands -- Reserve antibiotics for children younger than two years old with bilateral acute otitis media infections or for any child with otorrhea, researchers here recommended. For other children, watchful waiting seems justified
IDSA: Fluzone Safe and Immunogenic in Infants Ages Six to 12 Weeks
October 17th 2006TORONTO -- The Fluzone inactivated trivalent influenza vaccine, which is licensed for children older than six months and adults, is safe and immunogenic in infants from six and 12 weeks old, researchers reported here.
Risk Factors Identified for Complications After Sleep Apnea Surgery
October 16th 2006SEATTLE -- Surgery to correct obstructive sleep apnea (uvulopalatopharyngoplasty) is more likely to have complications if the condition is severe, a concurrent retrolingual procedure is done, BMI is high, or there are medical comorbidities, found a VA study.
RGPI: Telavancin as Effective as Vancomycin in Skin Infections
October 11th 2006NIAGARA-ON-THE-LAKE, Ontario -- The investigational novel antibiotic telavancin is as effective as vancomycin in treating complicated skin and skin structure infections caused by Gram-positive bacteria, researchers said today.
Thalidomide Analog Reduces Transfusion Needs in MDS Patients
October 5th 2006TAMPA, Fla. -- Patients with severe refractory anemia caused by myelodysplastic syndrome (MDS) with a 5q31 deletion could reduce or halt transfusion dependency after treatment with Revlimid (lenalidomide), reported investigators here.